

# MenACWY-CRM (Menveo®) & MenACWY-D (Menactra™)

| Vaccine   | Primary Schedule   | Comments  | Storage & Handling   |
|---|--|---|--|
| <b>Menveo®</b><br>(MenACWY-CRM)<br>(Novartis)       | Single dose: 0.5 mL (IM)<br><br>Reconstitution required (see administration) | Licensed for persons aged 2-55 years  | <ul style="list-style-type: none"> <li>Store MenACWY-D and MenACWY-CRM (lyophilized and liquid components) in the refrigerator between 35°F and 46°F (aim for 40°F)</li> <li>Do not freeze any component – do not use if this happens</li> </ul> |
| <b>Menactra™</b><br>(MenACWY-D)<br>(Sanofi Pasteur) | Single dose: 0.5 mL (IM)<br><br>No reconstitution required                   | Licensed for persons aged <b>9 months</b> -55 years.<br><b>PLEASE NOTE: Infants with asplenia should not be vaccinated before 2 years of age because of potential interference with pneumococcal vaccine.</b> |  |

## Meningococcal Vaccine Recommendations

### General Recommendations:

- Routinely recommended for all children at age 11-12 years; then give a booster dose at age 16 years.
- Adolescents who receive the first dose at age 13 through 15 years, should receive a one-time booster dose, preferably at age 16 through 18 years.
- Persons who receive their first dose of meningococcal conjugate vaccine at or after age 16 years do not need a booster dose.
- Routine vaccination of healthy persons who are not at increased risk for exposure to *N. meningitidis* is not recommended after 21 years of age.
- MenACWY-D may be used for persons aged **9 months**-55 years.
- MenACWY-CRM may be used for persons aged 2-55 years.
- Persons aged 56 years or older should receive MPSV4.
- Minimal interval between doses is 8 weeks.

### Recommendation for Persons Aged 2 Through 54 Years with Reduced Immune Response:

- Persons with persistent complement component deficiencies (e.g. C<sub>5</sub>—C<sub>9</sub>, properdin, factor H, or factor D) or asplenia should receive a 2-dose primary series administered 2 months apart and then receive a booster dose every 5 years.
- Adolescents aged 11 through 18 years with HIV infection should be routinely vaccinated with a 2-dose primary series.
- Other persons with HIV infection who are vaccinated should receive a 2-dose primary series administered 2 months apart.
- All other persons at increased risk for meningococcal disease (e.g. microbiologists or travelers to an epidemic or highly endemic country) should receive a single dose.



### Contraindications

- MenACWY-D:** Severe allergic reaction to a vaccine component or following a prior dose of vaccine.
- MenACWY-CRM:** Severe allergic reaction (e.g. Anaphylaxis) after a previous dose of MENACWY-CRM, any component if this vaccine, or any other CRM<sub>197</sub> diphtheria toxoid, or meningococcal-containing vaccine

### Precautions

- MenACWY-D and MenACWY-CRM:** A moderate or severe acute illness is a precaution.
- MenACWY-D and MenACWY-CRM:** Give during pregnancy only if clearly needed. (MPSV4 may be administered during pregnancy if indicated).

| Risk Group   | Primary Series                           | Booster Dose  |
|--|--|---|
| Persons aged 11 through 18 years   | 1 dose, preferably at age 11 or 12 years | At age 16 years if primary dose given at age 11 or 12 years                         |
|  |  | At age 16 through 18 years if primary dose given at age 13 through 15 years         |
|  |  | No booster dose needed if primary dose given on or after age 16 years               |
| HIV-infected persons in this age group   | 2 doses, 2 months apart                  | At age 16 years if primary dose given age 11 or 12 years                            |
|  |  | At age 16 through 18 years if primary dose given at age 13 thru 15 years            |
|  |  | No booster needed if primary dose given on or after age 16 years                    |
| Persons aged 2 through 55 years with persistent complement component deficiency or functional or anatomical asplenia | 2 doses, 2 months apart                  | Every 5 years   |
|  |  | At earliest opportunity if a 1-dose primary series administered, then every 5 years |
| Persons aged 2 through 55 years with prolonged increased risk for exposure   | 1 dose                                   | Persons aged 2 through 6 years: after 3 years                                       |
|  |  | Persons aged 7 years or older: after 5 years  |

| Age   | Subgroup   | Primary Vaccination  | Booster Dose   |
|---|--|--|--|
| 9 – 23 months of age, with high risk conditions | Children with complement deficiencies  | 2 doses of MenACWY-D, 3 months apart   | <b>If 1<sup>st</sup> dose received at age 9 months through 6 years and remain at increased risk for meningococcal disease</b> , should receive an additional dose of MenACWY-D 3 years after primary dose with boosters every 5 years. |
|   | Children with HIV, if another indication for vaccination exists                                  | 2 doses of MenACWY-D, 3 months apart   |  |
|   | All others in this age group recommended for vaccination (travelers to the Meningitis Belt, etc) | 2 doses of MenACWY-D, 3 months apart (infants receiving the vaccine prior to travel can receive the doses as early as 2 months apart |  |

### Adverse Reactions

- **Injection site:** pain redness, swelling.
- **Systemic:** headache, myalgia, nausea, malaise, chills, arthralgia, rash, fever.
- Some persons may develop syncope, sometimes resulting in falling with injury. Observation for 15 minutes after administration is recommended.

### Administration

- **MenACWY-D or MenACWY-CRM** may be administered simultaneously with inactivated or live vaccines.
- **MenACWY-D:** Vaccine is supplied in single-dose vials and single dose (latex-free) syringes. MenACWY-D in vials should not be drawn into a syringe until immediately before use. Administer vaccine as a single 0.5 mL IM injection into the deltoid region.
- **MenACWY-CRM:** vaccine requires reconstitution of the lyophilized MenA conjugate component with the liquid MenCYW-135 conjugate component. Do not use any other diluent. The reconstituted vaccine should be used immediately. Administer vaccine as a single 0.5 mL IM injection into the deltoid region.  
**Reconstitution for MenACWY-CRM:**
  - Withdraw liquid from vial containing the MenCYW-135 liquid component.
  - Insert MenCYW-135 liquid into MenA lyophilized component.
  - Gently invert or swirl until the vaccine is dissolved before administering vaccine.

